eFFECTOR’s Zotatifin (eFT226) Inhibited Tumor Growth and Caused Tumor Regression Across Diverse Receptor Tyrosine Kinase-Driven Tumor Types in Preclinical Models of Disease

by NASDAQ Market News April 27, 2020

NASDAQ Market News
Click here to email author

Generex Biotechnology Publishes Response to Congressional Letter Calling for COVID-19 Challenge Studies and Alternative Solution to Accelerate Vaccine Development

Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer

Ads